Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?

26 Feb 2025

Abstract excerpt

PURPOSE OF REVIEW: High-density lipoprotein (HDL) is integral to reverse cholesterol transport (RCT), a process considered to protect against atherosclerotic cardiovascular disease (ASCVD). We summarise findings from the recent AEGIS-II trial and discuss new opportunities for HDL therapeutics targeted at RCT. RECENT FINDINGS: Mendelian randomisation studies have suggested a causal association between the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Lipids, and Metabolism
Share to Diabetes, Cardiovascular Risks, and Lipoproteins
Share to Lipoproteins and Cardiovascular Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40009132
DOI: 10.1007/s11883-025-01281-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?PMID 40009132Read ↗

HDL, Atherosclerosis, and Emerging TherapiesSemantic proximity Read ↗

Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDLSemantic proximity Read ↗

HDL in the 21st Century: A Multifunctional Roadmap for Future HDL ResearchSemantic proximity Read ↗

Plasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation.Semantic proximity Read ↗

HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease - Insights from randomized clinical trials and human genetics.Semantic proximity Read ↗

Genetics of cholesterol efflux.Semantic proximity Read ↗

Advancing Beyond Failed High-density Lipoprotein Clinical Trials to Pharmacogenetic Studies of ADCY9 and Cholesterol Ester Transfer Protein Inhibition.Semantic proximity Read ↗

Treating low HDL--from bench to bedside.Semantic proximity Read ↗

Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protectionSemantic proximity Read ↗

No genetic evidence for an association of apolipoprotein A-I with cardiovascular outcomes at different LDL cholesterol levels: drug-target Mendelian randomization analyses.Semantic proximity Read ↗

The High-Density Lipoprotein Puzzle: Why Classic Epidemiology, Genetic Epidemiology, and Clinical Trials Conflict?Semantic proximity Read ↗

Non-HDL cholesterol as a therapeutic goal.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.